Castle Biosciences Inc

CSTL

Equity

ISIN null / Valor 48711401

NASDAQ (2026-03-27)

USD 23.53-4.74%

Castle Biosciences Inc
UMushroom community rating:

4.29 7 votes No rating yet

NegativeNeutralPositive

About company

Castle Biosciences Inc, founded in 2008, is a molecular diagnostics company that focuses on developing innovative tests to guide patient care in various medical conditions. The company offers a portfolio of proprietary tests, including DecisionDx®-Melanoma, DecisionDx®-SCC, DecisionDx®-UM, MyPath® Melanoma, TissueCypher® Barrett’s Esophagus, and IDgenetix®, which provide valuable insights to clinicians in dermatologic cancers, uveal melanoma, Barrett’s esophagus, and mental health conditions. These tests utilize gene expression profiles to predict the risk of metastasis, recurrence, and other clinical outcomes, helping healthcare providers make informed treatment decisions. Castle Biosciences aims to address unmet clinical needs and improve patient outcomes through its innovative diagnostic solutions.

Summarized from source with an LLMView SourceSector:

Revenue

Castle Biosciences Inc expects 2025 total revenue to exceed $340 million, above its prior guidance range of $327–$335 million.

Core test volume growth

Core revenue drivers (DecisionDx‑Melanoma and TissueCypher) increased: Q4 2025 core test reports were up 42% versus Q4 2024, and full‑year 2025 core test reports rose 37% versus 2024.

Quarter specifics

Q4 2025 counts: DecisionDx‑Melanoma 10,022 (vs. 8,672 Q4 2024); TissueCypher Barrett’s Esophagus 11,803 (vs. 6,672); DecisionDx‑SCC 3,971 (vs. 4,299; impacted by an April 24, 2025 Medicare coverage change and commercial refocus); MyPath Melanoma 1,045 (vs. 879); DecisionDx‑UM 395 (vs. 424).

Full‑year test volumes

Full‑year 2025: DecisionDx‑Melanoma 39,083 (2024: 36,008); TissueCypher 39,014 (2024: 20,956); DecisionDx‑SCC 17,294 (2024: 16,348); MyPath Melanoma 4,288 (2024: 3,909); DecisionDx‑UM 1,769 (2024: 1,699).

New product launch — AdvanceAD‑Tx

AdvanceAD‑Tx launched on a limited access basis in November 2025; of ~150 clinician offices granted access, more than 50% placed orders in the first five weeks.

Cash and investments

Year‑end 2025 cash and cash equivalents are expected to be approximately $116 million, with about $184 million in marketable investment securities (combined ≈ $300 million).

Discontinued test

IDgenetix was discontinued effective May 2025; related test reports fell to 3,605 in 2025 from 17,151 in 2024.

Preliminary and unaudited

These results are preliminary and unaudited and may change following completion of period‑end reporting and the audit; Castle notes forward‑looking statements and associated risks. Summarized from source with an LLMView Source

Key figures

17.1%1Y

3.98%3Y

-60.8%5Y

Performance

57.1%1Y

76.5%3Y

75.2%5Y

Volatility